

HM2024-04: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- new diagnosis of Chronic Lymphocytic Anemia (CLL) that has not been treated but requires treatment - at least up walking and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- CLL has been previously treated - known central nervous system involvement - confirmed progressive multifocal leukoencephalopathy (PML) - uncontrolled hypertension

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Chronic Lymphocytic Anemia, CLL

More Information

Description: This study is for patients with Chronic Lymphocytic Leukemia (CLL) that have not had any treatment yet. Study participants have an equal chance of either receiving a standard of care treatment (venetoclax plus obinutuzumab) or the combination of investigational drugs being studied (sonrotoclax plus zanubrutinib). The goal is to discover whether sonrotoclax plus zanubrutinib is more effective than the current standard of care treatments.

Study Contact: Sanjal Desai - desai171@umn.edu

Principal Investigator: Sanjal Desai

Phase: PHASE3

IRB

Number: STUDY00021639

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.